Amgen Sets Annual List Price for Osteoporosis Drug Evenity at $21,900
Amgen Sets Annual List Price for Osteoporosis Drug Evenity at $21,900
Novartis Eyes Late 2019 Launch for Wet AMD Drug
Novartis Eyes Late 2019 Launch for Wet AMD Drug
The top 15 pharma companies by 2018 revenue
The top 15 pharma companies by 2018 revenue
Keytruda continues its lung cancer land grab with another FDA nod
Keytruda continues its lung cancer land grab with another FDA nod
Gilead and Novo Nordisk Team up to Tackle NASH
Gilead and Novo Nordisk Team up to Tackle NASH
Done Deal: Bristol-Myers Squibb Shareholders Vote to Buy Celgene
Done Deal: Bristol-Myers Squibb Shareholders Vote to Buy Celgene
Gilead Sciences Cuts 150 Sales Jobs After Drugs Lose Patent Protection
Gilead Sciences Cuts 150 Sales Jobs After Drugs Lose Patent Protection
World Parkinson’s Day: How Science Is Battling the Disease
World Parkinson’s Day: How Science Is Battling the Disease
Η Novartis αφήνει ελεύθερη την Alcon
Η Novartis αφήνει ελεύθερη την Alcon
Janssen’s HIV Drug Symtuza Shows Long-Term Effect in Late Stage Trial
Janssen’s HIV Drug Symtuza Shows Long-Term Effect in Late Stage Trial
FDA Approves Amgen’s Evenity for Osteoporosis
FDA Approves Amgen’s Evenity for Osteoporosis
Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
Συνεργασία AsrtaZeneca και MSD στην ογκολογία
Συνεργασία AsrtaZeneca και MSD στην ογκολογία
EASL 2019 – Intercept builds a case for Ocaliva
EASL 2019 – Intercept builds a case for Ocaliva
AACR: BMS, clinging to Opdivo’s lung cancer share, highlights long-term data
AACR: BMS, clinging to Opdivo’s lung cancer share, highlights long-term data
7 Habits of Astonishingly Weak Leaders (and How Not to Be One)
7 Habits of Astonishingly Weak Leaders (and How Not to Be One)
